retatrutide glp-1 gip glucagon agonist Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA TrimRX | GLP-1 vs GIP:

The average participant lost more than 70 pounds in about 16 months

Addressing these challenges while capitalizing on innovations in drug design will be essential for optimizing patient outcomes and realizing the full potential of GLP-1based therapies

Hepatic glucagon increases gluconeogenesis and lipolysis via PKA/CREB activation, stimulates brown adipose tissue thermogenesis, and reduces hepatic triglyceride accumulation

He stresses that while patients desire for increased size is natural, sensational stories arent a substitute for medical truths

doi:10.2147/PPA.S277676 Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M

Your provider will explain their recommendation and discuss alternatives if you have a preference